Company Overview of Protein Sciences Corporation
Protein Sciences Corporation develops, manufactures, and commercializes vaccines and biopharmaceuticals for the prevention and treatment of various diseases. The company offers Flublok, a recombinant protein-based seasonal influenza vaccine; Panblok, a pandemic influenza vaccine; FluNhance that is used to enhance additive to influenza vaccines; and SARS (D3252), a Severe Acute Respiratory Syndrome vaccine that is used to elicit neutralizing antibodies to the virus. It also provides Baculovirus Expression Vector System, a platform technology used for the development of a range of vaccines and therapeutics, such as prophylactic vaccines, therapeutic vaccines, gene therapy, and biologic applica...
1000 Research Parkway
Meriden, CT 06450
Founded in 1983
Key Executives for Protein Sciences Corporation
Chief Executive Officer, President and Director
Chief Administrative Officer, Senior Vice President and Corporate Secretary
Senior Vice President of Manufacturing Operations
Senior Vice President of Quality
Compensation as of Fiscal Year 2017.
Protein Sciences Corporation Key Developments
Protein Sciences Corporation Announces Publication of Results from Influenza Study
Jun 22 17
Protein Sciences Corporation announced the publication of clinical trial results comparing Flublok Quadrivalent - the quadrivalent version of Flublok influenza vaccine - to a traditional egg-based quadrivalent inactivated vaccine. It showed that Flublok Quadrivalent provided significantly improved protection against laboratory confirmed influenza illness in older adults. The publication notes that approximately 9,000 people aged 50 and older were enrolled and randomized in an efficacy study designed to compare Flublok Quadrivalent to a traditional quadrivalent vaccine. People who were given Flublok Quadrivalent were over 40% less likely to develop culture-confirmed influenza. This data satisfies both pre-specified criteria for non-inferiority and superiority of Flublok over the traditional egg-based quadrivalent inactivated vaccine. Flublok Quadrivalent was approved by the FDA in October 2016 and will be available nationwide in prefilled syringes for the upcoming flu season. This study shows that Flublok Quadrivalent, produced with modern recombinant technology can provide better protection against confirmed influenza-like illness among older adults than standard-dose quadrivalent influenza vaccine produced with traditional technology. Flublok is the flu vaccine made without the use of eggs and therefore is not subject to the mutations that are sometimes introduced into the vaccine during the process of egg adaptation that can cause the traditional vaccines to be ineffective (Skowronski et al. (2014) PLOS ONE 9(3), e92153). Flublok contains three times more active ingredients than traditional vaccines and produced significantly higher immune responses to the A strains of influenza (especially H3N2) in the Flublok Quadrivalent study. Furthermore, Flublok Quadrivalent is the first and only high antigen-content quadrivalent flu vaccine that with its high efficacy makes it ideal for older adults and those with a compromised immune system. Flublok is highly purified and does not contain influenza virus, antibiotics, formaldehyde, preservatives, egg protein, latex, gluten or gelatin unlike other flu vaccines. Flublok Quadrivalent is FDA approved for adults 18 and older.
Protein Sciences Corporation Presents at BIO International Conference 2017, Jun-20-2017 03:00 PM
May 25 17
Protein Sciences Corporation Presents at BIO International Conference 2017, Jun-20-2017 03:00 PM. Venue: San Diego Convention Center, San Diego, CA 2865, United States. Speakers: Manon M. J. Cox, Chief Executive Officer, President and Director.
Protein Sciences Corporation Wins FDA Approval of an Extended Shelf Life for Flublok Quadrivalent from 6 Months to 9 Months
Apr 4 17
Protein Sciences Corporation announced that FDA approved an extended shelf life for Flublok Quadrivalent from 6 months to 9 months ensuring that Flublok can be used throughout the flu season. Trivalent Flublok was introduced to the market 4 years ago. Flublok Quadrivalent will be available in prefilled syringes during the upcoming flu season. Any licensed physician can order the product directly from Protein Sciences or from one of the distributors listed below. Locations carrying the vaccine will be added to the company's Flublok Finder on a daily basis starting in August to help people find a location near them. Flublok Quadrivalent protects against four strains of the influenza virus and has 3x more active ingredients than other quadrivalent flu vaccines, making it the only high-antigen quadrivalent vaccine on the market and a great option for seniors. Flublok Quadrivalent demonstrated better efficacy compared to a standard quadrivalent flu vaccine in adults 50 and older in a large clinical study, with recipients of Flublok being 43% less likely to get culture-confirmed influenza than those that received the standard vaccine.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 11, 2017